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Background and aims: Screening for oesophageal varices (OV) using conventional 
oesophagogastroduodenoscopy (C-OGD) is invasive and requires costly monitoring, 
recovery, and decontamination facilities. We aimed to evaluate the technical feasibility, 
acceptability and accuracy of a novel, portable, and disposable office-based transnasal 
endoscope (EG Scan™) compared to C-OGD as the reference standard.  
Methods: This was a prospective cohort study. Consecutive adult patients with liver 
cirrhosis were invited to participate. All subjects underwent the two procedures on the same 
day performed by two endoscopists in a blinded design. Patients completed preference and 
validated tolerability (10-point visual analogue scale (VAS)) questionnaires on day 0 and day 
14 post procedures.   
Results: 45 out of 50 patients (90%) completed both interventions. Mean age was 59 years 
and OV prevalence was 49%.  
Patients reported higher preference (percentage) and better experience (mean VAS) with 
EG Scan compared to C-OGD on day 0 (76.5% vs. 23.5%, p<0.001; 7.8 vs. 6.8, p=0.058, 
respectively) and day 14 (77.8% vs. 22.2%, p<0.001; 7.0 vs. 5.5, p=0.0013, respectively). 
Sensitivity and specificity of the EG Scan for the diagnosis of any size OV were 0.82 
(95%confidence interval (CI) 0.60-0.95), and 0.78 (95%CI 0.56-0.93), respectively. 
Corresponding values for the diagnosis of clinically significant (medium/large) OV were 0.92 
(95%CI 0.62-1.0), 0.97 (95%CI 0.84-1.0), respectively. No serious adverse events occurred.   
 Conclusions: EG Scan accuracy was higher for the diagnosis of medium/large OV 
compared to any size OV. Patients’ preference and overall experience of the EG Scan was 
favourable compared to C-OGD 14 days after procedures.   




 Conventional oesophagogastroduodenoscopy (C-OGD) is invasive and may not be 
cost-effective as a screening tool for oesophageal varices (OV). 
 The EG Scan™ is a novel portable and disposable transnasal endoscope which may be 
used as a rapid office-based screening test. 
 Novel data from this study demonstrate that the EG Scan™ was safe, successful, and 
appears to be acceptable to patients.  
 EG Scan™ was accurate in the detection of clinically significant OV. 
 
Introduction 
Screening for oesophageal varices (OV) using conventional oesophagogastroduodenoscopy 
(C-OGD) followed by primary prophylaxis is currently recommended for all patients with 
cirrhosis [1,2]. However, the cost-effectiveness of C-OGD as a screening tool in this context 
is doubtful [3]. The prevalence of OV is highly dependent on disease severity; and ranges 
from as low as 40% in patients with Child-Pugh class A to 70% in those with Child-Pugh 
class B/C [4]. This implies that a significant proportion of patients currently undergo serial 
negative endoscopies with no clinical benefit. Thus, having a more effective strategy for 
screening and stratifying which patients need C-OGD will have direct implications for 
patients and the healthcare system [1,2]. 
A large number of non-invasive tests for the detection of OV have been evaluated[5], but 
none have substituted C-OGD as the standard reference tests in current clinical 
practice[1,5]. C-OGD is performed in a hospital setting usually under conscious sedation to 
increase comfort and tolerability [6]. This leads to loss of work time on the day of procedures 
and the need for the patient to be accompanied home afterwards. Moreover, performing C-
OGD has many other logistical and cost considerations as it requires patient monitoring, 
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experienced nursing staff, recovery rooms and decontamination equipment [6]. Therefore, 
un-sedated ultrathin transnasal endoscopy (TNE) has been evaluated in this setting; 
however, the available devices still require decontamination facilities and are usually 
performed in dedicated endoscopy suites [7]. The need for controlled trials on office-based, 
portable TNE screening for OV was highlighted in recent guidelines from the British Society 
of Gastroenterology [2].  
The second generation E.G. scan™ (EG Scan™ II) is a novel transnasal video endoscope 
which is portable, lightweight, sedation-free, and has a disposable probe which eliminates 
the need for decontamination equipment; hence, may overcome the limitations of C-OGD for 
use as an office-based rapid screening test. Aedo et al [8], evaluated the accuracy of an 
early prototype of this device (ESOScan™) in the detection of various upper gastrointestinal 
pathologies with promising results. However, this early model had no air insufflation 
capability and did not allow examination in the retroflexion position, which may limit its utility 
for the assessment of OV size and extent. Moreover, the impact of this technique on 
patients’ preference and tolerability was not evaluated. The purpose of this study was to 
assess the technical feasibility, acceptability, and accuracy of the EG Scan™ II system for 
the detection of OV in patients with liver cirrhosis.     
Materials and methods  
Study design and settings  
This was a prospective diagnostic cohort study in a tertiary referral centre (Nottingham 
University Hospitals NHS Trust, Nottingham, United Kingdom) and all procedures were 
performed between July 31st 2012 and 25th February 2014. All the participants provided 
written informed consent and the study received approval from the East Midlands 
Nottingham 1 research ethics committee. The trial was prospectively registered on the 
ISRCTN registry (identifier: 70595405). This research was conducted and reported 
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according to the standards for the reporting of diagnostic accuracy studies (STARD) 
statement [9]. 
Participants 
Consecutive adult patients with known liver cirrhosis (confirmed by clinical, radiological, 
and/or histopathological criteria) who are scheduled to undergo C-OGD for screening or 
surveillance of OV at our hospital were invited to participate in this study. We excluded 
patients with recurrent epistaxis (more than once a week); complete nasal obstruction; 
disease of the nasal cavity; prior history of variceal bleeding (defined as haematemesis or 
melaena requiring hospital admission); and those who had band ligation therapy in the past 
12 weeks.    
Interventions 
All patients underwent TNE first using the EG scan followed by C-OGD on the same day. All 
EG Scan procedures were performed by a single experienced endoscopist (performed over 
1000 C-OGD procedures), but had limited prior experience in using the EG Scan device 
(performed 3 procedures on 3 volunteers). The operator was blinded to the results of any 
previous investigations. C-OGD procedures were performed by another two experienced 
endoscopists who were blinded to the findings of the EG Scan procedure. The size of OV 
was graded according to the American Association for the Study of Liver Diseases 
consensus classification system into either small or medium/large OV (small OV defined as 
small straight varices that usually disappear on air insufflation; medium OV defined as 
enlarged tortuous varices occupying less than one third of the lumen; and large OV defined 
as coil-shaped varices occupying more than one third of the lumen) [1]. Patients were asked 
to fill in validated questionnaires on day 0 and day 14 after the procedures.  
The EG Scan™ II system 
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The second generation EG Scan system (Intromedic Co. Ltd., Seoul, South Korea) (figure 1) 
consists of four main components: 
1. A single use probe (diameter 3.4 mm, length 1088 mm) which is made from human 
compliance plastic and contains: 
a) Capsule at the tip (diameter 6.1 mm) which produces images at a speed of 30 frames 
per second with a 125° field of view and 3-50 mm view depth. The camera capsule 
incorporates a complementary metal-oxide semiconductor (CMOS) image sensor 
with 400×400 pixel array. 
b) Bending wire to facilitate tip deflection (bending angle 160° up/160° down). 
c) Data connector to transmit captured images from the capsule to the processor. 
d) Air insufflation channel. 
2. A hand-held controller with an up/down lever to facilitate tip deflection. The probe is 
attached to the controller. 
3. An image processor which incorporates a free air displacement system (5L/min). Images 
are transmitted from the tip of the probe to the processor and then displayed on a laptop 
computer screen via USB connection.   
4. An air tube which connects the processor to the probe in order to facilitate air insufflation.    
Endoscopy procedures 
The EG Scan procedure was performed in an outpatient clinic room with the patient sitting in 
a chair next to the physician’s desk. Prior to commencing the procedure, participants were 
given a 100-ml liquid oral drink which is a mixture of water; orange cordial flavouring; a 
mucolytic (10 mls of 200 mg/ml N-acetylcysteine, Parvolex®, Recipharm Ltd, Ashton under 
Lyne, UK); and an anti-foaming agent (1ml of Simeticone 40 mg/ml, Infacol®, Forest 
Laboratories UK Ltd, Dartford, UK) in order to improve the visualization of the mucosa. A 
topical aerosol spray (Lidocaine Hydrochloride 5% and Phenylephrine Hydrochloride 0.5%; 
Pharmacy Production Unit, Queens Hospital, Burton on Trent, UK) was applied to the 
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patient’s nares (3-4 sprays) 3-5 minutes prior to the procedure. The endoscope was 
introduced into the right or left nares and advanced into the proximal oesophagus under 
direct vision. The operator carefully inspected the oesophagus and the gastroesophageal 
junction both in forward and retro-flexion views.  
Following the procedure, the probe was disconnected from the hand-held controller and 
discarded. The system was dismantled and stored in the accompanying suitcase (figure 1A). 
The C-OGD procedures were performed at our endoscopy suite using a 9.8-mm diameter 
high definition endoscope (GIF-H260, Olympus Keymed, Essex, UK). The procedure was 
performed after either a topical anaesthetic spray was applied to the posterior pharynx (5-10 
sprays, Lidocaine 10mg/dose, Xylocaine, AstraZeneca, Luton, UK) or under sedation with 
intravenous midazolam (Hameln pharmaceuticals ltd, Gloucester, United Kingdom), 
according to patient preference as per standard practice in the UK.    
Patient questionnaires 
All questionnaires were administered by the study coordinator and completed by patients 
after the endoscopist left the examination room. Patients’ tolerability was measured using a 
validated 10-point visual analogue scale (VAS) [10]. Patients were asked to describe their 
overall experience after each procedure by placing a cross on a line from “0” (worst ever 
experience) to “10” (best ever experience). We also measured the degree of gagging, 
choking, discomfort, and nasal pain (EG Scan only) using the same scale where “0” is none 
and “10” is severe. After completion of both procedures, patients were asked to choose 
which procedure they would prefer to have in the future if clinically indicated (EG Scan, or C-
OGD, or either). Tolerability and preference questionnaires were completed on the same day 
(day 0) and 2 weeks (day 14) after procedures (using prepaid self-addressed return 





Study outcome measures included:   
1. The technical feasibility, quality and safety of the endoscopic examinations (EG Scan 
and C-OGD) measured as: (i) rate of successful intubation (the ability to traverse the 
upper oesophageal sphincter and visualize the oesophageal mucosa) classified as 
successful or unsuccessful; (ii) rate of complete evaluation (visualization of the whole 
oesophagus and identification of  the landmarks: squamocolumnar junction, 
gastroesophageal junction [upper margin of gastric folds with stomach deflated] and the 
diaphragmatic hiatus) classified as complete = all three landmarks identified, incomplete 
= some landmarks identified, or unsuccessful; (iii) duration of examination (time from 
intubation to extubation for the EG Scan; and (iv) rate of adverse events including: 
withdrawal of consent, bleeding, perforation, or need for hospitalization assessed 
immediately and 14 days (telephone call from the study coordinator) after the 
procedures in all subjects. 
2. Patients’ acceptability of both procedures measured using validated questionnaires as 
detailed above. 
3. The real time accuracy of EG Scan (index test) in detecting any size OV and clinically 
significant (medium/large) OV using C-OGD as the reference standard. This was 
measured using sensitivity, specificity, and area under the receiver operating 
characteristic (AUROC) curve. 
4. Inter-observer agreement on the EG Scan and C-OGD findings (presence and grade of 
OV) measured using the Kappa statistic. Anonymized video clips were recorded for both 
EG Scan (n=45) and C-OGD (n=45) procedures, then edited to a length of 1-2 minutes. 
Nine blinded assessors (3 hepatologists, 3 gastroenterologists, and 3 trainee 
gastroenterologists) evaluated all the videos independently of each other and in random 
order. Prior to the evaluation stage, all observers received a 20-minute training session 
during which they reviewed 5 representative video clips and 10 still images for the EG 
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Scan (first 10 minutes), followed by the same number of videos and images for C-OGD 
(second 10 minutes) in order to demonstrate the presence, absence, and different 
grades of OV.  
Statistical analysis 
This was a pilot study to collect data which will help inform power calculations for future 
trials. We assessed a group 50 patients, based on a realistic recruitment target over 18 
months. We used paired t-test (normally distributed differences) and Wilcoxon signed rank 
test (non-normally distributed differences) to compare measurements of continuous 
variables between EG Scan and C-OGD procedures. The Chi-squared or Fisher exact tests 
were used to compare categorical variables. A p value of less than 0.05 was considered 
statistically significant. The kappa (κ) statistic was calculated to measure the degree for 
agreement after correcting for chance agreement [11]. The interpretation of κ-values was 
done according to the guidance provided by Landis and Koch where values <0 indicate no 
agreement; 0–0.20 = slight; 0.21–0.40 = fair; 0.41–0.60 = moderate; 0.61–0.80 = substantial; 
and 0.81–1 = almost perfect agreement [12]. Statistical computations were performed using 
the Stata version 12.0 software (Stata Corporation, College Station, Texas, USA). 
Results 
Baseline Characteristics 
50 patients were recruited to the study and 45 (90%) completed both procedures. 43 out of 
45 patients (93%) had compensated cirrhosis. Prevalence of OV was 49% (27% 
medium/large) (table 1).  
Technical feasibility, quality and acceptability 
3 patients failed EG Scan (6%) and 2 failed C-OGD (4%), p=0.882 (figure 2). 26 out of 45 
(58%) C-OGD procedures were performed under sedation using intravenous midazolam 
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(mean dose 3.2 mg; +/-0.9) with or without intravenous pethidine (median dose 0 mg; IQR 0-
50).  
The mean duration of EG Scan examination was 8.1 minutes (+/-2.4). Results of technical 
feasibility, quality, safety and acceptability are presented in table 2. Data on procedure 
preference and experience (VAS) are also shown in figure 3 and figure 4, respectively. Four 
patients (8.5%) experienced minor self-limiting epistaxis. No serious adverse events 
occurred. 
Accuracy and interobserver agreement 
Sensitivity, specificity and AUROC of the EG Scan for the diagnosis of any OV were 0.82 
(95%confidence interval (CI) 0.60-0.95), 0.78 (95%CI 0.56-0.93), and 0.80 (95%CI 0.68-
0.92), respectively. Corresponding values for the diagnosis of medium/large OV were 0.92 
(95%CI 0.62-1.0), 0.97 (95%CI 0.84-1.0), and 0.94 (95%CI 0.86-1.0), respectively. 
For EG Scan, K values (all observers) for the presence of any OV, small OV and 
medium/large OV were 0.45 (95%CI 0.40-0.49), 0.19 (95%CI 015-0.24) and 0.47 (95%CI 
0.42-0.52), respectively. For C-OGD, corresponding values were 0.54 (95%CI 0.49-0.59), 
0.22 (95%CI 0.17-0.26) and 0.67 (95%CI 0.62-0.71), respectively. Example findings of EG 
Scan are shown in figure 5.  
Discussion 
Principal findings 
This is the first study evaluating the feasibility and clinical utility of the EG Scan II device as 
an office-based screening tool for OV in a selected cohort of patients with liver cirrhosis. We 
demonstrate that the trans-nasal technique with EG scan can be performed safely and it is 
acceptable by patients compared to C-OGD. 
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Unsedated TNE techniques have been developed in an attempt to address some of the 
limitations of C-OGD with regards to tolerability, acceptability, and the need for sedation with 
costly recovery and monitoring suites [13]. We recently reported results from a systematic 
review and meta-analysis of 34 studies (6,659 patients) demonstrating that there was no 
significant difference in technical success rate of currently available TNE devices (<5.9 mm 
insertion diameter) compared to C-OGD [13]. Moreover, patients preferred TNE over C-OGD 
in all 10 studies (1,418 patients) where this outcome was measured [13]. Success rate of EG 
Scan was not significantly different from C-OGD in the current study (table 2) and preference 
data were also highly encouraging. Patients reported higher preference for EG Scan 
compared to C-OGD on both day 0 (76.5% vs. 23.5%, p<0.001) and day 14 (77.8% vs. 
22.2%, p<0.001) after procedures independent of the use of sedation for C-OGD (table 2). 
The patients’ experience (VAS) was  better with EG Scan; however, there was no significant 
difference in experience when sedation was used for C-OGD (table 2). The use of propofol 
for C-OGD is likely to make it even more attractive to patients compared to EG Scan. The 
EG Scan performance in this study appears to be favourable compared to other currently 
available minimally invasive markers. Oesophageal capsule endoscopy is a well-tolerated 
and promising tool but reports on sensitivity (for the detection of any size OV) have been 
conflicting and ranged from 63% to 100% in different studies [14]. This may be related to the 
inability to insufflate air during examination with oesophageal capsule endoscopy. Moreover, 
the cost-effectiveness of this technique compared to C-OGD remains doubtful [15]. 
While the EG Scan was accurate in detecting clinically significant (medium/large) OV, it was 
inferior to C-OGD when small OV were included in the analysis. This finding could be due to 
a limitation of the EG Scan imaging quality or could equally be a result of poor agreement 
between the EG Scan and C-OGD operators on the presence or absence of small OV. All 
operators received training and followed a standardized protocol for examination and image 
documentation in order to minimize observer bias. However, it is well known that OV size 
and shape can vary significantly depending on the amount of air insufflation and phase of 
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respiration during examination [16]. The inter-observer agreement on the EG Scan diagnosis 
of medium/large OV was moderate (K=0.47), while agreement on small OV was slight 
(k=0.19). Interestingly, these patterns were similar in case of C-OGD (K for medium/large 
OV = 0.67 and K for small OV = 0.22). These values suggest that the performance of both 
procedures in detecting small OV varies significantly across different observers. Moreover, 
they draw attention to the fact that C-OGD may not be an objective reference standard in the 
setting of small OV. These findings may need to be confirmed in a larger study which should 
also examine whether agreement varies between observers with variable levels of 
experience. We could not investigate this parameter due to the small number of videos 
included in our study. Our results are comparable to other studies reporting poor agreement 
on C-OGD findings of small OV compared to medium/large OV [17]. Nevertheless, data from 
C-OGD interobserver agreement studies should be interpreted with caution, because of the 
variation in classification systems, assessment methods (still images vs. video recordings) 
and number as well as expertise of observers [18]. Moreover, all C-OGD studies were 
performed in the 1980’s and early 1990’s using outdated imaging technologies with a 
significantly inferior image quality [19,20].    
The accuracy of conventional TNE (non-portable and non-disposable) in the detection of OV 
has been evaluated in a recent study by Choe et al, [7] where the authors reported excellent 
sensitivity and specificity of 100% (95%CI 93%-100%) and 93% (95%CI 79%-98%), 
respectively, for the detection of any OV. All patients underwent TNE and C-OGD within two 
weeks by two different operators, however, the diagnosis of whether OV were present or 
absent was made on the basis of post-hoc review of still images from both procedures by 
three blinded endoscopists. This type of study design may lead to significant bias because 
both index test and reference standard results were interpreted by the same individuals 
[9,21].  
Study strengths and limitations 
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This pilot study had strengths and limitations. The trial design, conduct, and reporting 
conforms to current guidelines for undertaking diagnostic accuracy studies which is an 
important strength [9,21]. We selected a consecutive group of patients who are 
representative of those for which the test will be used in clinical practice. Although the EG 
Scan (index test) and C-OGD (reference standard) operators were blinded to the findings of 
either tests, it remains difficult to rule out operator bias since the investigators were not 
blinded to the intervention, nevertheless, this limitation is true of any endoscopic study. 
Moreover, all the EG Scan procedures were performed by a single endoscopist (SSS) with 
an in interest in the TNE technique. We attempted to address this by examining the 
interobserver agreement on the EG Scan diagnosis among other endoscopists with varying 
levels of expertise. Similarly, participation bias may also exist, since patients who agree to 
undergo TNE may be more motivated to tolerate the procedure and find it acceptable. 
We used validated VAS [10] and 3-item (EG Scan or C-OGD or either) questionnaires to 
measure tolerability and preference, respectively. Day 0 questionnaires were administered 
by the trial coordinator face to face in order to improve response rate (100%) and minimize 
response bias (0% non-responders) [22], while day 14 were self-administered 
questionnaires to help minimize interviewer bias [22]. The response rate on day 14 was 87% 
(39 out of 45) for VAS (table 2) and 82% (37 out of 45) for preference (figure 2), therefore 
response bias remains unlikely. Furthermore, in the latter questionnaire, patients were 
offered the choice of “either” for their procedure preference to minimize forced choice bias, 
where respondents who have no preference will be forced to select an answer (EG Scan or 
C-OGD) that may or may not reflect their true feelings [22]. Finally, we cannot rule out social 
desirability or obsequiousness bias where respondents may alter their questionnaire 
responses in the direction they perceive to be desired by the investigator [22], however, this 
limitation pertains to the majority of questionnaire study designs. Patients were offered 
neither monetary compensation nor any other incentive (such as an earlier appointment) to 
participate in the study.   
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Implications for clinical practice 
A major limitation of the currently available transnasal endoscopes is the lack of portability 
and the requirement for decontamination facilities. Hence, TNE procedures have, so far, 
been performed in the endoscopy unit and not routinely used for OV screening, possibly 
because endoscopists perceive little added value in performing TNE when C-OGD is readily 
available and can simultaneously be utilized for variceal band ligation if necessary [7]. 
Screening for OV using C-OGD is reportedly under-implemented in clinical practice, in 
particular, within the community hospitals setting [23]. Hepatologists were more likely to 
screen patients compared to general gastroenterologists and more likely to initiate primary 
prophylaxis [23]. 
The EG Scan may address these limitations by offering a portable and disposable 
endoscopic imaging tool that can be used as a pre-screening test in the office to reduce the 
number of unnecessary endoscopies and potentially improve screening uptake by offering a 
well tolerated and more preferred test to patients. Moreover, this strategy may facilitate 
better targeting of C-OGD resources for patients who are shown to have OV on EG scan 
and will therefore require interventional measures such as variceal band ligation or beta-
blocker therapy. Data from our study will help inform future trials to evaluate the cost-
effectiveness of EG Scan screening followed by C-OGD only when OV are detected 
compared to the current strategy of universal C-OGD screening.  
The EG Scan provides direct visualization of the oesophagus with a binary outcome similar 
to the interpretation of C-OGD, but it also has limitations compared to other non-invasive 
markers such as blood tests, in particular, the EG Scan is operator dependent and requires 
training and expertise for the diagnosis and grading of OV which determines the need for 
prophylaxis. These factors may limit its wide spread use especially by non-
gastroenterologists in the community. Nonetheless, office-based TNE can be performed 
successfully by physician extenders after a short training program and the learning curve for 
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the detection of OV remains to be determined in future larger studies [24]. The risk of 
epistaxis will also need to be carefully weighed when using this technique in cirrhotic 
patients.   
Conclusions 
The EG Scan screening in this pilot study of patients with liver cirrhosis was feasible, safe, 
and remained highly acceptable compared to C-OGD 14 days after procedures. EG Scan 
accuracy was high for the detection of clinically significant medium/large OV, but this 
reduced when small OV were included. This is could be due to the poor interobserver 
agreement on the diagnosis of small OV using either EG Scan or C-OGD. As a result, 
utilizing accuracy alone as a study endpoint may not be adequate. Future studies should 
focus on the effectiveness of EG Scan in routine clinical practice and cost effectiveness in 
the overall health care system. Important effectiveness endpoints of a new OV screening 
strategy could be the number of C-OGDs saved; or the proportion of variceal bleeds or 
deaths prevented compared to the current standard of care [25].  
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Table 1: Baseline characteristics of the study cohort (n=45). Data presented as number (%) 
or mean (+/- standard deviation (SD)) or median (interquartile range (IQR)) 
Variable Value 
Age 59 (+/-11) 
Male gender 33 (73.3%) 
White ethnicity 45 (100%) 
Aetiology of cirrhosis  
Alcohol 19 (42.2%) 
Non-alcoholic fatty liver disease 12 (26.7%) 
Hepatitis C virus 3 (6.7%) 
Hepatitis C virus and alcohol 2 (4.4%) 
Hereditary Haemochromatosis 4 (8.9%) 
Other (AIH n=2, PBC n=2, Unknown n=1) 5 (11.1%) 
Child Pugh class  
A/B/C 34 (75.6%)/10 (22.2%)/1 (2.2%) 
Child Pugh score 6.2 (+/-1.3) 
Oesophageal varices  
Yes 22 (49%) 
     Small (grade1) 10 (46%) 
     Medium/large (grade 2/3) 12 (54%) 
No 23 (51%) 
Gastric varices 3 (6.7%) 
Prothrombin time 12.3 (+/-1.9) 
Platelet count 134 (IQR 89-196) 
Spleen diameter 13.1 (+/-2.1) 




Diabetes 15 (33.3%) 
Hypertension 15 (33.3%) 
Chronic obstructive pulmonary disease 7 (15.6%) 
Ischemic heart disease 4 (8.9%) 
Screening indication 27 (60%) 
Surveillance indication 18 (40%) 
















Table 2: Quality, safety, and acceptability of endoscopic assessments. Data presented 
as number (%) or mean (+/- standard deviation (SD)) or median (interquartile range (IQR)).  
Variable EG Scan C-OGD P value 
Rate of successful intubation 47 (94%) 48 (96%) § 0.882 
Rate of complete evaluation 44 (88%) 46 (92%) † 0.411 
Adverse events scales 
(0= none, 10= worst) 
   
Gagging/retching 1 (IQR 0-3) 4 (IQR 0-8) <0.001  
Choking 0 (IQR 0-2) 0.5 (IQR 0-5 <0.001 
Discomfort 2 (IQR 0-3) 3 (IQR 0-7) 0.011 
Nasal pain (EG Scan only) 0 (IQR 0-1) -  
Preference day 0 total (n=34)‡ 26 (76.5%) 8 (23.5%) <0.001 
sedation subgroup (n=20) 13 (65%) 7 (35%) <0.001 
no sedation subgroup (n=14) 13 (92.9%) 1 (7.1%) <0.001 
VAS score day 0 total (n=45) 7.8 (+/-2.2) 6.8 (+/-3.0) 0.058 
sedation subgroup (n=26) 7.4 (+/-2.6) 7.9 (+/-2.3) 0.477 
no sedation subgroup (n=19) 8.4 (+/-1.4) 5.2 (+/-3.3) <0.001  
Preference day 14 total (n=27)ʄ 21 (77.8%) 6 (22.2%) <0.001 
sedation subgroup (n=16) 11 (68.8%) 5 (31.2%) <0.001  
no sedation subgroup (n=11) 10 (90.9%) 1 (9.1%) 0.001 
VAS score day 14 total (n=39)¶ 7.0 (+/-2.3) 5.0 (+/-3.2) <0.001 
sedation subgroup (n=22) 6.4 (+/-2.6) 5.8 (+/-3.1) 0.383 
no sedation subgroup (n=17) 7.8 (+/-1.5) 4.0 (+/-3.2) <0.001 
C-OGD, conventional oesophagogastroduodenoscopy. § C-OGD failed in two patients (not tolerated on two 
attempts by one patient and the other had a very high systolic blood pressure of 230 mmHg). † Two patients 
withdrew consent halfway through the procedure. ‡ n=34/45 expressed preference for either EG Scan or C-OGD 
while the remaining 11 expressed no preference (either). ʄ n=27/39 expressed preference for either EG Scan or 
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C-OGD while the remaining 12 expressed no preference (either). ¶ n=39/45 (87%) returned the 14-day 
questionnaire and reported VAS scores.  
Figure legends 
Figure 1: The EG Scan™ II system. A) the portable case with four main parts; B) the image 
processor (top left), disposable probe (top right), air tube (bottom right) and hand-held 
controller (bottom left); C) the system connected and ready for use; D) close view of the 
capsule probe tip.  
Figure 2: Study flowchart. OV, oesophageal varices; C-OGD, conventional 
oesophagogastroduodenoscopy; SBP, systolic blood pressure. † 5 cases false positive on 
EG Scan all were graded as small OV; ‡ EG Scan missed 4 cases of OV (small n=3, 
medium/large n=1). 
Figure 3: Procedure preference (patients were asked which procedure they would prefer to 
have in the future if clinically indicated). C-OGD, conventional 
oesophagogastroduodenoscopy. 
Figure 4: Procedure experience measured at day 0 and day 14 using a 10-point visual 
analogue scale (0=worst, 10=best). Thick horizontal line represents median, hollow diamond 
symbol represents mean. C-OGD, conventional oesophagogastroduodenoscopy.   
Figure 5: Example findings of EG Scan. A) Normal oesophagus; B) Grade 1/small 
oesophageal varices (OV); C) Grade 2/medium OV; D) Grade 3/large OV; E) OV with red 
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